Hanyu Medical Lands $77 Million in D+ Round for Cardiovascular Devices

Shanghai 's Hanyu Medical completed a $77 million D+ funding for its minimally invasive mitral valve device, ValveClamp. ValveClamp is a globally patented mitral valve repair device used to treat mitral regurgitation. Established in late 2016, Hanyu is planning an IPO on the Shanghai STAR Board. The D+ round was led by YF Capital. In mid-2020, Hanyu closed an $80 million D round. More details.... Share this with colleagues: // //